ACB vs SMTI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Aurora Cannabis Inc. (ACB) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 1/9—indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and persistent negative profitability metrics (ROE: -15.51%, ROA: -4.36%) suggest high bankruptcy risk, especially given the company's negative earnings and declining cash flow. Despite a low price-to-book (0.49) and price-to-sales (0.52), the stock trades at a significant discount due to deteriorating fundamentals and a 96.9% 5-year decline. The lack of analyst coverage and neutral insider activity further erode confidence in near-term recovery.
SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.
Compare Another Pair
Related Comparisons
ACB vs SMTI: Head-to-Head Comparison
This page compares Aurora Cannabis Inc. (ACB) and Sanara MedTech Inc. (SMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.